



Financial Tear Sheet

Corporate Profile

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Seven registration studies are currently advancing related to six Array-owned or partnered drugs: binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Cascadian Therapeutics).

Primary IR Contact

Jason Haddock
Chief Financial Officer
E-mail: ir@arraybiopharma.com

Tricia Haugeto
Director, Corporate Communications
and Investor Relations
Phone: (303) 386-1193
E-mail:
Tricia.Haugeto@arraybiopharma.com

Stock Performance

ARRAY (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$8.43
Change (%)	▲ 0.04 (0.48%)
Volume	490,164
52 Week Low	\$3.10
Market Cap	\$1,438,991,879
Rolling EPS	-0.72
PE Ratio	N/A

Shares Outstanding 170,800,223

Data as of 05/24/17 12:10 p.m. ET



Recent Headlines

05/10/17 - 8:00 a.m.
Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2017

05/09/17 - 4:01 p.m.
Array BioPharma Announces Positive Top-Line Results from Part 2 of the Phase 3 COLUMBUS Study of Binimetinib and Encorafenib for BRAF-Mutant Melanoma


05/08/17 - 8:00 a.m.
Array BioPharma Announces Strategic Collaboration with Merck

Upcoming Events

There are currently no events scheduled.

Analyst Estimates / Ratings

Mean Recommendation: 1.8



EPS Trend

		Current	30 Days Ago	90 Days Ago
QTR	Jun 17	-0.21	-0.21	-0.22
QTR	Sep 17	-0.17	-0.15	-0.14
QTR	Dec 17	-0.18	-0.16	-0.12
QTR	Mar 18	-0.17	-0.15	-0.09
FY	Jun 17	-0.76	-0.71	-0.73
FY	Jun 18	-0.89	-0.81	-0.73

SEC Filings

Filing Date	Form	
05/10/17	10-Q	
05/10/17	8-K	
05/10/17	8-K	
05/08/17	8-K	

Ownership Summary

Shareholders

	Holders	Value (\$MM)	% O/S	Shares
Institution	268	1,558.11	103.0	175,891,763
Mutual Fund	250	733.23	48.5	82,830,639
Insider *	10	3.83	0.3	432,290

*Insider values reflect direct beneficial ownership.

Top Holders

	Shares Held	% O/S	Share Change	Filing Date
Fidelity Management & Research Company	23,275,836	13.6	-1,404,300	03/31/17
The Vanguard Group, Inc.	16,993,415	10.0	6,156,120	03/31/17
OrbiMed Advisors, LLC	14,182,900	8.3	-1,905,900	03/31/17
Redmile Group, LLC	12,765,862	7.5	-3,852,914	03/31/17
BlackRock Institutional Trust Company, N.A.	11,949,839	7.0	-1,534	03/31/17
State Street Global Advisors (US)	8,264,775	4.8	1,837,047	03/31/17
Millennium Management LLC	6,494,344	3.8	4,642,648	03/31/17
Franklin Advisers, Inc.	5,986,126	3.5	450,766	03/31/17
venBio Select Advisor LLC	3,780,000	2.2	3,620,000	03/31/17
Pinnacle Associates Ltd.	3,063,577	1.8	-145,930	03/31/17

Powered By **EDGAR**Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed